Radiation Therapy is expected to be the highest revenue generating segment, accounting for an expected CAGR rate of 10.9% during 2022 – 2032. The rising prevalence of glioblastoma multiforme, increased R&D, and favorable regulatory scenarios are all projected to fuel the market growth. The presence of a good drug pipeline is expected to be a significant driver for the glioblastoma […]